New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Non-small cell lung cancer (NSCLC) is refractory to systemic chemotherapy, compared with small cell lung cancer. Until recently, only five drugs--cisplatin, vindesine, mitomycin, ifosfamide, and vinblastine--could produce overall response rates of 15% against NSCLC. However, recent efforts have contributed to the development of new drugs with activity against NSCLC, including irinotecan hydrochloride (CPT-11), paclitaxel, docetaxel, vinorelbine, and gemcitabine. Combination chemotherapy against NSCLC using these agents has demonstrated high response rates. In Japan, various combination chemotherapy and combined-modality regimens employing CPT-11 have been evaluated for their efficacy. Randomized controlled trials to establish new state-of-the-art treatments for NSCLC are ongoing.
Saijo
N
N
Pharmacology Division, National Cancer Center Research Institute and Hospital, Tokyo, Japan.
D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002227:Carbazoles / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D005960:Glucosides / Q000494:pharmacology; D006801:Humans; D000077146:Irinotecan; D007564:Japan; D008175:Lung Neoplasms / Q000188:drug therapy*; D016685:Mitomycin / Q000494:pharmacology; D008937:Mitomycins; D009374:Neoplasms, Experimental / Q000188:drug therapy; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D011684:Purine Nucleosides / Q000494:pharmacology; D019311:Staurosporine / Q000031:analogs & derivatives; D043823:Taxoids; D016896:Treatment Outcome; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine
D000470:Alkaloids; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D002227:Carbazoles; D005960:Glucosides; D008937:Mitomycins; C092476:NB 506; D011684:Purine Nucleosides; D043823:Taxoids; C057625:KW 2149; D000077143:Docetaxel; D016685:Mitomycin; D014747:Vinblastine; D000077146:Irinotecan; C054852:7-hydroxystaurosporine; C092296:KRN 5500; D019311:Staurosporine; C095887:exatecan; D017239:Paclitaxel; D000077235:Vinorelbine; D002166:Camptothecin